Skip to main content

Patou Gary's Form 4 filing

Xenon Pharmaceuticals Inc.XENE · filed Dec 15, 2023

Accession no.
0000950170-23-070841
Filed
Dec 15, 2023
Trade date
Dec 13, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 10 non-derivative transactions and 3 derivative transactions. Open-market sales total $759.0K. It was filed 2 days after the trade.

This filing was later replaced by the amendment 0000950170-23-070912 (Dec 15, 2023). Trade tables on this site use the amended version.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Patou GaryCIK 0001283535Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 13, 2023Common SharesMOption exerciseAcquired+6,378$9.85F2+$62,823.329,951Direct
Dec 13, 2023Common SharesFTax withholdingDisposed−1,278$39.68F3−$50,711.0428,673Direct
Dec 13, 2023Common SharesSSaleDisposed−5,100$38.94F4−$198,59423,573Direct
Dec 13, 2023Common SharesMOption exerciseAcquired+2,880$9.85F2+$28,36826,453Direct
Dec 13, 2023Common SharesFTax withholdingDisposed−577$39.68F3−$22,895.3625,876Direct
Dec 13, 2023Common SharesSSaleDisposed−2,303$39.10F5−$90,047.323,573Direct
Dec 13, 2023Common SharesMOption exerciseAcquired+5,144$9.00+$46,29628,717Direct
Dec 13, 2023Common SharesFTax withholdingDisposed−1,167$39.68F3−$46,306.5627,550Direct
Dec 13, 2023Common SharesSSaleDisposed−3,977$39.84−$158,443.6823,573Direct
Dec 13, 2023Common SharesSSaleDisposed−7,598$41.05F6−$311,897.94,902Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 13, 2023Common SharesMOption exerciseDisposed−6,378$0.00$00Direct
Dec 13, 2023Common SharesMOption exerciseDisposed−2,800$0.00$00Direct
Dec 13, 2023Common SharesMOption exerciseDisposed−5,144$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Referenced by the price of 2 transactions in Table I.

F3

Represents the closing price of the Company's common shares in U.S. dollars on December 12, 2023, which was converted to a Canadian dollar amount for purposes of net settlement calculations.

Referenced by the price of 3 transactions in Table I.

F4

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.81 to $39.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

F5

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $39.04 to $39.16, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

F6

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.06, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)